Johnson & Johnson
Financials
Valuation Metrics
Johnson & Johnson's Market Cap is $651.27B. At end of 2025 it was $503.37B. Ranked #19 of 3,118 in US market (top 0.6%), #7 of 1,644 on NYSE (top 0.4%), #2 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.8%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $651.27B | US#19/3,118 Sec#2/265 |
| Revenue | $99.33B | US#50/3,118 Sec#1/265 |
| Net Income | $16.09B | US#35/3,118 Sec#3/265 |
| Total Assets | $197.43B | US#102/3,118 Sec#2/265 |
| Net Assets | $81.53B | US#44/3,118 Sec#2/265 |
| Employees | 138,200 | US#68/3,118 Sec#1/265 |
| Value | ||
| P/E | 40.46x | US#1,809/3,118 Sec#48/265 |
| P/B | 7.99x | US#2,531/3,118 Sec#185/265 |
| P/S | 6.56x | US#2,503/3,118 Sec#94/265 |
| EV/EBITDA | 22.04x | US#2,002/3,118 Sec#51/265 |
| FCF Yield | 3.16% | US#1,788/3,118 Sec#53/265 |
| Profitability | ||
| ROE | 19.74% | US#597/3,118 Sec#31/265 |
| ROA | 8.15% | US#644/3,118 Sec#42/265 |
| Op. Margin | 25.70% | US#647/3,118 Sec#32/265 |
| Revenue Growth | 7.80% | US#1,467/3,118 Sec#106/265 |
| Earnings Growth | -35.92% | US#1,640/3,118 Sec#41/265 |
| Financial Health | ||
| Debt Ratio | 142.15% | US#1,434/3,118 Sec#182/265 |
| Total Debt | $44.65B | US#102/3,118 Sec#7/265 |
| FCF | $20.59B | US#25/3,118 Sec#1/265 |
| Cash | $16.91B | US#70/3,118 Sec#1/265 |
| Current Ratio | 1.02x | US#2,255/3,118 Sec#253/265 |
| Net Debt/EBITDA | 0.90x | US#931/3,118 Sec#43/265 |
| Dividend | ||
| Div. Yield | 1.95% | US#958/3,118 Sec#17/265 |
| Div. Growth | 3.80% | US#910/3,118 Sec#12/265 |
| Performance | ||
| 1Y Return | 44.92% | US#540/3,118 Sec#76/265 |
| 1M Return | 5.67% | US#1,434/3,118 Sec#83/265 |
| From 52W High | -4.07% | US#256/3,118 Sec#23/265 |
| 1Y MDD | -10.96% | US#59/3,118 Sec#1/265 |
| Trading | ||
| Volume | 6,151,630 shares | US#389/3,118 Sec#25/265 |
| Trading Value | $1.66B | US#70/3,118 Sec#5/265 |
| Per Share | ||
| EPS | $6.69 | US#497/3,118 Sec#16/265 |
| BPS | $33.87 | US#782/3,118 Sec#15/265 |
Company Info
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.